An in vitro demonstration of overcoming drug resistance in SKOV3 TR and MCF7 ADR with targeted delivery of polymer pro-drug conjugates

Journal of Drug Targeting

Volumn 25, Issue 5, 2017, Pages 436-450

  Bhattarai, Prashant ^a   Vance, Dylan ^a   Hatefi, Arash ^b   Khaw, Ban An ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Bispecific antibodies; drug resistance; MCF7 ADR; SKOV3 TR; targeted polymer pro drug conjugates

Indexed keywords

BIOTIN; BISPECIFIC ANTIBODY; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; POLYMER; PRODRUG; ANTINEOPLASTIC AGENT; CHLORPROMAZINE;

ARTICLE; BIOTINYLATION; BREAST CARCINOMA; CANCER RESISTANCE; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MCF-7 CELL LINE; PRIORITY JOURNAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHLORPROMAZINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; FEMALE; HUMANS; IN VITRO TECHNIQUES; MCF-7 CELLS; POLYMERS; PRODRUGS;

EID: 85008394558     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/1061186X.2016.1271421     Document Type: Article

References (43)

1. Št’astnỳ M, Strohalm J, Plocova D, et al. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier. Eur J Cancer 1999;35:459–66.
2. Horwitz SB., Taxol (Ptxl):mechanisms of action. Ann Oncol 1994;5:S3–S6.
3. Liang XJ, Chen C, Zhao Y, Wang PC., Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol 2010;596:467–88.
4. Plenderleith I., Treating the treatment:toxicity of cancer chemotherapy. Can Fam Physician 1999;36:1827–30.
5. Haag R, Kratz F., Polymer therapeutics:concepts and applications. Angew Chem Int Ed Engl 2006;45:1198–215.
6. Duncan R., Polymer conjugates as anticancer nanomedicines. Nature Rev Cancer 2006;6:688–701.
7. Larson N, Ghandehari H., Polymeric conjugates for drug delivery. Chem Mater 2012;24:840–53.
8. Yusuf RZ, Duan Z, Lamendola DE, et al. Paclitaxel resistance:molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3:1–19.
9. Spanswick VJ, Craddock C, Sekhar M, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002;100:224–9.
10. Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy Clin Cancer Res 2001;7:3314–24.
11. Ringsdorf H., Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975;51:135–53.
12. Khandare J, Minko T., Polymer–drug conjugates:progress in polymeric pro-drugs. Prog Polym Sci 2006;31:359–97.
13. Greco F, Vincent MJ. Combination therapy:opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009;61:1203–13.
14. Cao Y, Suresh MR., Bispecific antibodies as novel bioconjugates. Bioconjug Chem 1998;9:635–44.
15. Wadhwa S, Mumper R., Polymer-drug conjugates for anticancer drug delivery. Crit Rev Ther Drug Carrier Syst 2015;32:215–45.
16. Kontermann R., Dual targeting strategies with bispecific antibodies. mAbs 2012;4:182–97.
17. Patil V, Gada K, Panwar R, et al. In vitro demonstration of enhanced prostate cancer toxicity:pretargeting with Bombesin bispecific complexes and targeting with polymer-drug-conjugates. J Drug Deliv 2013;21:1012–21.
18. Khaw B, Tekabe Y, Johnson LL., Imaging experimental atherosclerotic lesions in ApoE knockout mice:enhanced targeting with Z2D3-anti-DTPA bispecific antibody and 99mTc-labeled negatively charged polymers. J Nucl Med 2006;47:868–76.
19. Hana M, Lva Q, Tanga X, et al. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of Dox via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Rel 2012;163:136–44.
20. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH., Pretargeted radioimmunotherapy of cancer:progress step by step. J Nucl Med 2003;44:400–11.
21. Russell-Jones G, McTavish K, et al. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 2004;98:1625–33.
22. Chen S, Zhao X, Chen J, et al. Mechanism-based tumor-targeting drug delivery system. validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem 2010;21:979–98.
23. Chen Y, Li N, Yang Y, Liu Y., A dual targeting cyclodextrin/gold nanoparticle conjugate as a scaffold for solubilization and delivery of Ptxl. RSC Adv 2015;5:8938–41.
24. Khaw B, Gada K, Patil V, et al. Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts:targeted polymer drug conjugates for cancer diagnosis and therapy. Eur J Nucl Med Mol Imaging 2014;41:1603–16.
25. Gada K., Targeted delivery of radioisotope or chemotherapeutic loaded pro-drug-polymers after pre-targeting tumors with bispecific antibody complex [dissertation]. Northeastern University; 2011.
26. Thorn C, Oshiro C, Marsh S, et al. Doxorubicin pathways:pharmacodynamics and adverse effects. Pharmacogenet Genom 2012;21:440–6.
27. Zhenfeng D, Fellar A, Penson R, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology:analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999;5:3346–3348.
28. Batist G, Tulpule A, Sinha BK, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986;261:15544–9.
29. Gada K, Patil V, Panwar R, et al. Companion targeted diagnosis and therapy:bispecific HER2 affibody-anti-DTPA-Fab for target-specific delivery of Tc-99m-labeled-polymers or DTPA-Dox-conjugated-polymers. J Nucl Med 2012;53:115.
30. Bayer EA, Ben-Hur H, Wilchek M., A sensitive enzyme assay for biotin, avidin, and streptavidin. Anal Biochem 1986;154:367–70.
31. Nitecki D, Stoltenberg I, Goodman J., Qualitative and quantitative determination of mixtures of amino acids using 2,4,6-trinitrobenzenesulfonic acid. Anal Biochem 1967;19:344–50.
32. Li C, Yu D, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998;58:2404–9.
33. Wiranowska M, Colina LO, Johnson JO., Clathrin-mediated entry and cellular localization of chlorotoxin in human glioma. Cancer Cell Int 2011;11:27.
34. Andersen K, Vaugha M., Gel centrifugation chromatography for macromolecular separations. J Chromatogr 1982;240:1–8.
35. Didziapetris R, Japertas P, Avdeef A, Petrauskas A., Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003;11:391–406.
36. Kathawala RJ, Gupta P, Ashby CR, Jr, Chen ZS., The modulation of ABC transporter-mediated multidrug resistance in cancer:a review of the past decade. Drug Resist Update 2015;18:1–17.
37. Li X, Gao L, Cui Q, et al. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene 2012;31:4979–86.
38. Shapira A, Davidson I, Avni N, et al. β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma:stability, target-activated release and cytotoxicity. Eur J Pharm Biopharm 2012;80:298–305.
39. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310–16.
40. Kim CK, Ghosh P, Pagliuca C, et al. Entrapment of hydrophobic drugs in nanoparticle monolayers with efficient release into cancer cells. J Am Chem Soc 2009;131:1360–1.
41. Kang L, Gao Z, Huang W, et al. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B 2015;5:169–75.
42. Zhang M, Akbulut M., Adsorption, desorption, and removal of polymeric nanomedicine on and from cellulose surfaces:effect of size. Langmuir 2011;27:12550–9.
43. Minko T, Kopecková P, Pozharov V, Kopecek J., HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Rel 1998;54:223–33.